Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease

@article{Toedter2009RelationshipOC,
  title={Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease},
  author={Gary P Toedter and Marion A. Blank and Yinghua Lang and Dion Chen and W J Sandborn and Willem J. S. de Villiers},
  journal={The American Journal of Gastroenterology},
  year={2009},
  volume={104},
  pages={2768-2773}
}
OBJECTIVES:Ustekinumab induction therapy was studied in a placebo-controlled trial of patients with Crohn's disease (CD; n=104). In patients receiving ustekinumab, 49% achieved clinical response at week 8 vs. 40% for placebo (P=0.34). In a subgroup of patients previously treated with infliximab (n=49), 59% receiving ustekinumab responded vs. 26% receiving placebo (P=0.02).METHODS:C-reactive protein (CRP) concentrations were analyzed from serum collected at baseline and at week 8. Change from… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

A randomized trial of ustekinumab a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn’s disease

  • BG Feagan, RN Fedorak
  • Gastroenterology
  • 2008

Similar Papers

Loading similar papers…